Treatment for Multiple Sclerosis
A patent family: one line of work, grouped by real continuity rather than by a technology label
inferred from titles. 5 of these applications claim priority to application 15/527,252, filed May 16, 2017. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
| Patent | Title | Holder | Status | Expires | Time remaining | Confidence |
|---|---|---|---|---|---|---|
| US 8,399,514 | Treatment for Multiple Sclerosis In force · High confidence | Biogen Ma Inc. | In force | High confidence | ||
| US 10,399,924 | Deuterium Substituted Fumarate Derivatives In force · High confidence | Biogen Ma Inc. | In force | High confidence | ||
| US 10,172,794 | Controlled Release Dosage Form for Once Daily Administration of Dimethyl Fumarate In force · High confidence | Biogen Ma Inc. | In force | High confidence | ||
| US 10,391,160 | Dimethyl Fumarate and Vaccination Regimens In force · High confidence | Biogen Ma Inc. | In force | High confidence | ||
| US 10,959,972 | Methods of Treating Multiple Sclerosis In force · Medium confidence | Biogen Ma Inc. | In force | Medium confidence | ||
| US 11,007,166 | Methods of Treating Multiple Sclerosis In force · Medium confidence | Biogen Ma Inc. | In force | Medium confidence | ||
| US 11,007,167 | Methods of Treating Multiple Sclerosis In force · Medium confidence | Biogen Ma Inc. | In force | Medium confidence | ||
| US 11,129,806 | Methods of Treating Multiple Sclerosis In force · Medium confidence | Biogen Ma Inc. | In force | Medium confidence | ||
| US 11,246,850 | Methods of Treating Multiple Sclerosis In force · High confidence | Biogen Ma Inc. | In force | High confidence | ||
| US 10,555,993 | Dimethyl Fumarate and Vaccination Regimens Lapsed Feb 11, 2024 on the fee record Medium confidence | Biogen Ma Inc. | Lapsed Feb 11, 2024 on the fee record | Medium confidence | ||
| 41 more patents in this group · Pro | ||||||
10 of 51 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
Pro members see all 51, including 4 expired and 1 expiring within the 18 months from Nov 18, 2026.
9 of these are in force and held by Biogen Ma Inc..
Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.